Resistance to targeted therapies in breast cancer

We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast can...

Full description

Saved in:
Bibliographic Details
Other Authors Prosperi, Jenifer R. (Editor)
Format Electronic eBook
LanguageEnglish
Published Cham, Switzerland : Springer, [2017]
SeriesResistance to targeted anti-cancer therapeutics ; v. 16.
Subjects
Online AccessPlný text

Cover

Loading…